- Home
- GPRK vs RIGL Comparison
GPRK vs RIGL Comparison
Compare GPRK & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPRK
- RIGL
- Stock Information
- Founded
- GPRK 2002
- RIGL 1996
- Country
- GPRK Colombia
- RIGL United States
- Employees
- GPRK N/A
- RIGL N/A
- Industry
- GPRK Oil & Gas Production
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- GPRK Energy
- RIGL Health Care
- Exchange
- GPRK Nasdaq
- RIGL Nasdaq
- Market Cap
- GPRK 343.3M
- RIGL 335.5M
- IPO Year
- GPRK N/A
- RIGL 2000
- Fundamental
- Price
- GPRK $6.73
- RIGL $18.66
- Analyst Decision
- GPRK Buy
- RIGL Buy
- Analyst Count
- GPRK 1
- RIGL 5
- Target Price
- GPRK $11.00
- RIGL $36.40
- AVG Volume (30 Days)
- GPRK 925.5K
- RIGL 170.2K
- Earning Date
- GPRK 08-13-2025
- RIGL 08-05-2025
- Dividend Yield
- GPRK 8.70%
- RIGL N/A
- EPS Growth
- GPRK N/A
- RIGL N/A
- EPS
- GPRK 1.51
- RIGL 2.08
- Revenue
- GPRK $630,771,000.00
- RIGL $203,077,000.00
- Revenue This Year
- GPRK N/A
- RIGL $14.41
- Revenue Next Year
- GPRK $5.80
- RIGL $15.97
- P/E Ratio
- GPRK $4.60
- RIGL $8.92
- Revenue Growth
- GPRK N/A
- RIGL 70.16
- 52 Week Low
- GPRK $5.66
- RIGL $7.48
- 52 Week High
- GPRK $11.72
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- GPRK 45.85
- RIGL 37.91
- Support Level
- GPRK $6.85
- RIGL $18.35
- Resistance Level
- GPRK $7.86
- RIGL $19.21
- Average True Range (ATR)
- GPRK 0.30
- RIGL 0.89
- MACD
- GPRK -0.05
- RIGL -0.33
- Stochastic Oscillator
- GPRK 14.04
- RIGL 2.15
About GPRK Geopark Ltd
GeoPark Ltd is a Latin American oil and gas exploration and production company with assets in Colombia, Ecuador, Chile, Brazil, and Argentina. The company generates revenue from the sale of crude oil, condensate, and natural gas, net of value-added tax and discounts related to the sale and overriding royalties due to the ex-owners of oil and gas properties where the royalty arrangements represent a retained working interest in the property.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.